VYOME HOLDINGS, INC. Net Income (Loss) Available to Common Stockholders, Basic
VYOME HOLDINGS, INC. (HIND) reported Net Income (Loss) Available to Common Stockholders, Basic of -$1.58 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2024-11-14
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-09-30 was -$1.58M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-06-30 was -$1.59M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2024-03-31 was -$2.19M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2023-12-31 was -$1.70M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2023 was -$11.39M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2022 was -$46.21M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$63.15M.
- VYOME HOLDINGS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$21.63M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | -$1.58M 10-Q · filed 2024-11-14 | -$3.18M derived: sum of 2 quarters · filed 2024-11-14 | -$5.37M 10-Q · filed 2024-11-14 | -$7.07M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2024-06-30 | -$1.59M 10-Q · filed 2024-08-14 | -$3.79M 10-Q · filed 2024-08-14 | -$5.49M derived: sum of 3 quarters · filed 2024-08-14 | -$9.02M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2024-03-31 | -$2.19M 10-Q · filed 2024-05-15 | -$3.89M derived: sum of 2 quarters · filed 2024-05-15 | -$7.42M derived: sum of 3 quarters · filed 2024-11-14 | -$10.92M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$5.23M derived: sum of 2 quarters · filed 2024-11-14 | -$8.72M derived: sum of 3 quarters · filed 2024-11-14 | -$11.39M 10-K · filed 2024-04-01 | ||||
| 2023-09-30 | -$3.53M 10-Q · filed 2024-11-14 | -$7.03M derived: sum of 2 quarters · filed 2024-11-14 | -$9.69M 10-Q · filed 2024-11-14 | -$26.16M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | -$3.49M 10-Q · filed 2024-08-14 | -$6.16M 10-Q · filed 2024-08-14 | -$22.62M derived: sum of 3 quarters · filed 2024-08-14 | -$34.81M derived: sum of 4 quarters · filed 2024-08-14 | ||||
| 2023-03-31 | -$2.66M 10-Q · filed 2024-05-15 | -$19.13M derived: sum of 2 quarters · filed 2024-05-15 | -$31.32M derived: sum of 3 quarters · filed 2024-05-15 | -$40.76M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | -$16.47M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$28.66M derived: sum of 2 quarters · filed 2024-04-01 | -$38.10M derived: sum of 3 quarters · filed 2024-04-01 | -$46.21M 10-K · filed 2024-04-01 | ||||
| 2022-09-30 | -$12.19M 10-Q · filed 2023-11-09 | -$11.81M 10-Q · filed 2022-11-14 | -$21.63M derived: sum of 2 quarters · filed 2023-11-09 | -$29.75M 10-Q · filed 2023-11-09 | -$29.60M 10-Q · filed 2022-11-14 | -$66.99M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$9.44M 10-Q · filed 2023-08-07 | -$9.58M 10-Q · filed 2022-08-19 | -$17.56M 10-Q · filed 2023-08-07 | -$17.79M 10-Q · filed 2022-08-19 | -$54.81M derived: sum of 3 quarters · filed 2023-08-07 | -$71.94M derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | -$8.12M 10-Q · filed 2023-05-15 | -$8.21M 10-Q · filed 2022-05-23 | -$45.36M derived: sum of 2 quarters · filed 2023-05-15 | -$62.50M derived: sum of 3 quarters · filed 2023-05-15 | -$66.39M derived: sum of 4 quarters · filed 2023-05-15 | |||
| 2021-12-31 | -$37.25M derived: 10-K 12 month − 10-K 9 month · filed 2023-04-17 | -$54.38M derived: sum of 2 quarters · filed 2023-04-17 | -$58.27M derived: sum of 3 quarters · filed 2023-04-17 | -$63.15M 10-K · filed 2023-04-17 | -$61.93M 10-K · filed 2022-04-08 | |||
| 2021-09-30 | -$17.13M 10-K · filed 2023-04-17 | -$17.70M 10-Q · filed 2021-11-12 | -$21.02M derived: sum of 2 quarters · filed 2023-04-17 | -$25.90M 10-K · filed 2023-04-17 | -$26.48M 10-Q · filed 2021-11-12 | -$34.43M derived: sum of 4 quarters · filed 2023-04-17 | ||
| 2021-06-30 | -$3.89M 10-K · filed 2023-04-17 | -$3.90M 10-Q · filed 2021-08-16 | -$8.76M 10-K · filed 2023-04-17 | -$8.78M 10-Q · filed 2021-08-16 | -$17.30M derived: sum of 3 quarters · filed 2023-04-17 | -$22.48M derived: sum of 4 quarters · filed 2023-04-17 | ||
| 2021-03-31 | -$4.87M 10-Q · filed 2022-05-23 | -$13.41M derived: sum of 2 quarters · filed 2022-05-23 | -$18.59M derived: sum of 3 quarters · filed 2022-05-23 | -$22.19M derived: sum of 4 quarters · filed 2022-05-23 | ||||
| 2020-12-31 | -$8.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-08 | -$13.71M derived: sum of 2 quarters · filed 2022-04-08 | -$17.32M derived: sum of 3 quarters · filed 2022-04-08 | -$21.63M 10-K · filed 2022-04-08 | ||||
| 2020-09-30 | -$5.18M 10-Q · filed 2021-11-12 | -$8.78M derived: sum of 2 quarters · filed 2021-11-12 | -$13.09M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$3.60M 10-Q · filed 2021-11-12 | -$7.92M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |